What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data

Pamela J. Atherton, Britta Jasperson, Andrea Nibbe, Kate A. Clement-Brown, Cristine Allmer, Paul Novotny, Charles Erlichman, Jeff A Sloan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of Research: Event charts are a novel way of presenting data from pharmaceutical phase I clinical trials. We applied event chart methodology to summarize clinically significant changes in quality of life (QOL) data over time for oncology patients enrolled in North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials. Methods: Recent developments in QOL research have led to a number of definitions for clinically significant changes in oncology QOL measures. Many approaches suggest that on a 0 to 100 point scale, changes of <10 are small, 10 to 20 are moderate, and more than 20 points are large differences in QOL scores. This taxonomy is analogous to the tracking methodology invoked for the monitoring of toxicity data via National Cancer Institute Common Toxicity Criteria guidelines. This categorization was combined with event chart methodology to summarize QOL data over time for patients enrolled in oncology clinical trials. Event charts were compared to both the scatter plot approach and Kaplan-Meier time-to-event graphical representations. Results: The event chart method proved superior to plotting raw scores over time since at-risk individuals were identified with greater facility and censored or missing data were incorporated more readily due to the intent-to-treat nature of this method. Furthermore, event charts identified time points where patients may have experienced potential crises in QOL and where interventions could be employed. Conclusions: The event chart provides an innovative method for summarizing individual patient QOL data over time. This methodology has the potential for use as a tracking device in oncology clinical trials. In this sense, we can record QOL "events" and potentially intervene based upon the observed magnitude of changes in scores.

Original languageEnglish (US)
Pages (from-to)11-21
Number of pages11
JournalDrug Information Journal
Volume37
Issue number1
StatePublished - 2003

Fingerprint

Oncology
Quality of Life
Toxicity
Clinical Trials
Taxonomies
Clinical Trials, Phase I
National Cancer Institute (U.S.)
Research
Monitoring
Neoplasms
Pharmaceutical Preparations
Guidelines
Equipment and Supplies

Keywords

  • Clinical trials
  • Event chart
  • Oncology
  • Phase 1 studies
  • Quality of life

ASJC Scopus subject areas

  • Health Informatics
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Nursing(all)

Cite this

What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data. / Atherton, Pamela J.; Jasperson, Britta; Nibbe, Andrea; Clement-Brown, Kate A.; Allmer, Cristine; Novotny, Paul; Erlichman, Charles; Sloan, Jeff A.

In: Drug Information Journal, Vol. 37, No. 1, 2003, p. 11-21.

Research output: Contribution to journalArticle

Atherton, PJ, Jasperson, B, Nibbe, A, Clement-Brown, KA, Allmer, C, Novotny, P, Erlichman, C & Sloan, JA 2003, 'What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data', Drug Information Journal, vol. 37, no. 1, pp. 11-21.
Atherton, Pamela J. ; Jasperson, Britta ; Nibbe, Andrea ; Clement-Brown, Kate A. ; Allmer, Cristine ; Novotny, Paul ; Erlichman, Charles ; Sloan, Jeff A. / What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data. In: Drug Information Journal. 2003 ; Vol. 37, No. 1. pp. 11-21.
@article{42293abedf5a4d0292e1071074e0fdf9,
title = "What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data",
abstract = "Purpose of Research: Event charts are a novel way of presenting data from pharmaceutical phase I clinical trials. We applied event chart methodology to summarize clinically significant changes in quality of life (QOL) data over time for oncology patients enrolled in North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials. Methods: Recent developments in QOL research have led to a number of definitions for clinically significant changes in oncology QOL measures. Many approaches suggest that on a 0 to 100 point scale, changes of <10 are small, 10 to 20 are moderate, and more than 20 points are large differences in QOL scores. This taxonomy is analogous to the tracking methodology invoked for the monitoring of toxicity data via National Cancer Institute Common Toxicity Criteria guidelines. This categorization was combined with event chart methodology to summarize QOL data over time for patients enrolled in oncology clinical trials. Event charts were compared to both the scatter plot approach and Kaplan-Meier time-to-event graphical representations. Results: The event chart method proved superior to plotting raw scores over time since at-risk individuals were identified with greater facility and censored or missing data were incorporated more readily due to the intent-to-treat nature of this method. Furthermore, event charts identified time points where patients may have experienced potential crises in QOL and where interventions could be employed. Conclusions: The event chart provides an innovative method for summarizing individual patient QOL data over time. This methodology has the potential for use as a tracking device in oncology clinical trials. In this sense, we can record QOL {"}events{"} and potentially intervene based upon the observed magnitude of changes in scores.",
keywords = "Clinical trials, Event chart, Oncology, Phase 1 studies, Quality of life",
author = "Atherton, {Pamela J.} and Britta Jasperson and Andrea Nibbe and Clement-Brown, {Kate A.} and Cristine Allmer and Paul Novotny and Charles Erlichman and Sloan, {Jeff A}",
year = "2003",
language = "English (US)",
volume = "37",
pages = "11--21",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "1",

}

TY - JOUR

T1 - What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data

AU - Atherton, Pamela J.

AU - Jasperson, Britta

AU - Nibbe, Andrea

AU - Clement-Brown, Kate A.

AU - Allmer, Cristine

AU - Novotny, Paul

AU - Erlichman, Charles

AU - Sloan, Jeff A

PY - 2003

Y1 - 2003

N2 - Purpose of Research: Event charts are a novel way of presenting data from pharmaceutical phase I clinical trials. We applied event chart methodology to summarize clinically significant changes in quality of life (QOL) data over time for oncology patients enrolled in North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials. Methods: Recent developments in QOL research have led to a number of definitions for clinically significant changes in oncology QOL measures. Many approaches suggest that on a 0 to 100 point scale, changes of <10 are small, 10 to 20 are moderate, and more than 20 points are large differences in QOL scores. This taxonomy is analogous to the tracking methodology invoked for the monitoring of toxicity data via National Cancer Institute Common Toxicity Criteria guidelines. This categorization was combined with event chart methodology to summarize QOL data over time for patients enrolled in oncology clinical trials. Event charts were compared to both the scatter plot approach and Kaplan-Meier time-to-event graphical representations. Results: The event chart method proved superior to plotting raw scores over time since at-risk individuals were identified with greater facility and censored or missing data were incorporated more readily due to the intent-to-treat nature of this method. Furthermore, event charts identified time points where patients may have experienced potential crises in QOL and where interventions could be employed. Conclusions: The event chart provides an innovative method for summarizing individual patient QOL data over time. This methodology has the potential for use as a tracking device in oncology clinical trials. In this sense, we can record QOL "events" and potentially intervene based upon the observed magnitude of changes in scores.

AB - Purpose of Research: Event charts are a novel way of presenting data from pharmaceutical phase I clinical trials. We applied event chart methodology to summarize clinically significant changes in quality of life (QOL) data over time for oncology patients enrolled in North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials. Methods: Recent developments in QOL research have led to a number of definitions for clinically significant changes in oncology QOL measures. Many approaches suggest that on a 0 to 100 point scale, changes of <10 are small, 10 to 20 are moderate, and more than 20 points are large differences in QOL scores. This taxonomy is analogous to the tracking methodology invoked for the monitoring of toxicity data via National Cancer Institute Common Toxicity Criteria guidelines. This categorization was combined with event chart methodology to summarize QOL data over time for patients enrolled in oncology clinical trials. Event charts were compared to both the scatter plot approach and Kaplan-Meier time-to-event graphical representations. Results: The event chart method proved superior to plotting raw scores over time since at-risk individuals were identified with greater facility and censored or missing data were incorporated more readily due to the intent-to-treat nature of this method. Furthermore, event charts identified time points where patients may have experienced potential crises in QOL and where interventions could be employed. Conclusions: The event chart provides an innovative method for summarizing individual patient QOL data over time. This methodology has the potential for use as a tracking device in oncology clinical trials. In this sense, we can record QOL "events" and potentially intervene based upon the observed magnitude of changes in scores.

KW - Clinical trials

KW - Event chart

KW - Oncology

KW - Phase 1 studies

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0142184291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142184291&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0142184291

VL - 37

SP - 11

EP - 21

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 1

ER -